We are Heidelberg Epignostix, a pioneering start-up composed of a dedicated team of experts in the field of DNA methylation-based tumor classification. Based in Heidelberg, Germany, our company is built upon the rich knowledge and extensive research experience of our team.

At Heidelberg Epignostix, our mission is to revolutionize tumor classification by harnessing the power of methylation-based models. By combining cutting-edge technology, advanced computational methods, and our team’s deep expertise, we aim to provide precise and reliable solutions for tumour classification, which may ultimately lead to improved diagnosis, prognosis, and treatment decisions.

Our team comprises leading physicians, scientists, and bioinformaticians who have a comprehensive understanding of the complexities of cancer biology, genetics, and epigenetics. With a strong focus on methylation patterns, we have developed innovative AI algorithms and predictive models that leverage the unique characteristics of DNA methylation to identify and classify tumors with high accuracy.

Through our extensive collaboration with clinical partners, we have gained invaluable insights into the challenges faced by clinicians and researchers in accurately characterising tumors, tailoring treatment strategies, and ultimately improving patient outcomes. Our commitment to bridging the gap between cutting-edge research and practical applications has driven us to establish Heidelberg Epignostix, enabling us to translate our scientific discoveries into actionable solutions that can make a tangible impact in the field of oncology.

We are dedicated to providing state-of-the-art methylation-based classification tools and services to healthcare professionals, researchers, and pharmaceutical companies worldwide. Whether it’s assisting in the development of novel therapeutics, or supporting population-scale studies, our solutions offer a comprehensive and precise understanding of tumor subtypes and their underlying biology.

At Heidelberg Epignostix, we are passionate about transforming cancer care through innovation, collaboration, and the relentless pursuit of scientific excellence. We are excited to be at the forefront of the rapidly evolving field of methylation-based tumor classification, and we look forward to partnering with you in our shared mission to conquer cancer.